Drug combination study for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body and continues to grow despite hormone therapy.
- You have already tried at least one medicine like enzalutamide, darolutamide, apalutamide, or abiraterone.
- You have measurable tumors (on scans) and are expected to live at least 3 more months.
- You are generally well enough to carry out daily activities (ECOG performance status 0 or 1).
- You have adequate organ and bone marrow function, and no other serious medical conditions or untreated infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.